Breakthrough Medical Device
On August 10th, 2021, the FDA completed an extensive review process and designated GyroStim as a Breakthrough Medical Device, stating GyroStim has: “a reasonable expectation for providing more effective treatment relative to the current standard of care for balance disorders and vestibular dysfunction.”
The Breakthrough Device designation is a monumental accomplishment and a significant distinction that sets GyroStim apart from all other devices in its category: GyroStim is the first and only device for the treatment of balance disorders and vestibular dysfunction the FDA has designated as a Breakthrough Medical Device.
Dr. Kim Fox, DPT is a graduate of the University of Maryland School of Medicine at Baltimore and the University of Montana School of Physical Therapy.
AVORA, LLC is a privately owned and operated healthcare company where the patient comes first. Copyright 2010-2023.